home / stock / trvi / trvi quote
Last: | $ |
---|---|
Change Percent: | -3.42% |
Open: | $5.36 |
Close: | $5.0413 |
High: | $5.38 |
Low: | $4.82 |
Volume: | 4,689 |
Last Trade Date Time: | 02/12/2020 04:42:08 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $5.36 | $5.0413 | $5.38 | $4.82 | 4,689 | 02-12-2020 |
$ | $5.1466 | $5.22 | $5.22 | $5.0033 | 781 | 02-11-2020 |
$ | $5.31 | $5.31 | $5.31 | $5.0468 | 1,246 | 02-10-2020 |
$ | $N/A | $5.2579 | $N/A | $N/A | 256 | 02-07-2020 |
$ | $5.11 | $5.2579 | $5.2579 | $5.11 | 900 | 02-06-2020 |
$ | $4.89 | $5.38 | $5.38 | $4.89 | 1,204 | 02-05-2020 |
$ | $4.8755 | $4.6495 | $4.8755 | $4.6495 | 1,691 | 02-04-2020 |
$ | $4.85 | $4.67 | $4.88 | $4.6298 | 2,545 | 02-03-2020 |
$ | $5.03 | $4.98 | $5.14 | $4.78 | 10,185 | 01-31-2020 |
$ | $5.0323 | $5.25 | $5.25 | $4.7943 | 3,338 | 01-30-2020 |
$ | $5.08 | $5.34 | $5.37 | $4.7277 | 7,263 | 01-29-2020 |
$ | $5.14 | $5.14 | $5.14 | $5.14 | 360 | 01-28-2020 |
$ | $4.84 | $4.86 | $5.23 | $4.84 | 1,888 | 01-27-2020 |
$ | $5.18 | $5.18 | $5.18 | $4.7182 | 10,651 | 01-24-2020 |
$ | $4.96 | $4.99 | $5.09 | $4.6205 | 6,957 | 01-23-2020 |
$ | $5.0252 | $5.17 | $5.17 | $5.024 | 1,212 | 01-22-2020 |
$ | $5.10 | $5.20 | $5.23 | $5.0001 | 5,159 | 01-21-2020 |
$ | $5.37 | $5.33 | $5.3881 | $5.03 | 5,820 | 01-20-2020 |
$ | $5.37 | $5.33 | $5.3881 | $5.03 | 5,820 | 01-17-2020 |
$ | $5.0979 | $5.35 | $5.35 | $5.0979 | 3,283 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 PR Newswire Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn. , May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc...